论文部分内容阅读
本文报道了■例皮肤T细胞淋巴瘤(CTCL)患者对单独肌肉注射重组人γ干扰素(rIFN-γ)治疗后的反应情况。受试者年龄为39～67岁,分别处于6个不同的病程阶段,受试者4周前皆经过标准的局部或/和全身性的治疗,有些人用视黄醛、rIFN-α2a或放射性标记的单克隆抗体进行了试验性的(?)疗,但所有病人从未使用过rIFN-γ。疗程至少8周,治疗第1周的剂量按0.25mg/m~2/天,如无毒性不良反应,第2周起剂量增加0.5mg/m~2/天(Ⅰ期试验中确定的最大耐受
This article reports the response of patients with cutaneous T-cell lymphoma (CTCL) to treatment with rIFN-γ administered intramuscularly alone. Subjects ranged in age from 39 to 67 years at 6 different disease stages. Subjects underwent standard local and / or systemic treatment 4 weeks prior. Some were treated with retinal, rIFN-α2a, or radioactive Labeled monoclonal antibodies were tested (?), But all patients had never used rIFN-γ. The course of treatment for at least 8 weeks, the first week of treatment dose 0.25mg / m ~ 2 / day, such as non-toxic adverse reactions, the first two weeks from the dose increased 0.5mg / m ~ 2 / day By